$MCK

Winners And Losers Of Q2: McKesson (NYSE:MCK) Vs The Rest Of The Healthcare Providers & Services Stocks

McKesson (MCK) fell 9.1% post-earnings despite a solid quarter. AdaptHealth (AHCO) missed revenue and EBITDA estimates, down 46.2%. Elevance Health (ELV) beat revenue and EPS estimates but lost customers, down 7.4%. Quest (DGX) topped expectations, up 12.6%.

Original reporting
Published Aug 19, 2026, 12:38 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 19, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Winners And Losers Of Q2: McKesson (NYSE:MCK) Vs The Rest Of The Healthcare Providers & Services Stocks — source image
Decision brief

The 30-second read

$MCKBearishMed
01

Why it matters

Earnings releases cause varied price moves, highlighting sector rotation.

02

Market read

Earnings-driven price swings provide short‑term trading opportunities across the healthcare services space.

03

What to watch

Member loss at ELV may be temporary; AHCO's revenue growth still outpaces peers.

Relevance 8/10Novelty 8/10Timing: post‑earnings today

Background

Quarterly earnings season for healthcare providers and services.

Company-level read

Ticker impact

$MCKBearishHigh confidence
Context

Q2 earnings released; stock down 9.1% since report.

Expected impact

Potential further downside if guidance remains weak.

Evidence & confidence

Revenue and earnings fell short of expectations, prompting a 9% drop.

$AHCOBearishHigh confidence
Context

Q2 earnings released; stock down 46.2% since report.

Expected impact

Likely continued pressure unless guidance improves.

Evidence & confidence

Revenue up 12.7% YoY but missed estimates; full‑year guidance also missed, driving a large decline.

$ELVBearishMedium confidence
Context

Q2 earnings released; stock down 7.4% since report.

Expected impact

Modest further downside expected.

Evidence & confidence

Revenue flat, slight EPS beat, but member loss signals weaker future growth.

$DGXBullishHigh confidence
Context

Q2 earnings released; stock up 12.6% since report.

Expected impact

Potential upside continuation if guidance stays strong.

Evidence & confidence

Revenue up 10.2% YoY and beat estimates, leading to a double‑digit gain.

Market effects

Healthcare services sector shows divergent performance across peers.

U.S. healthcare stocks may see broader volatility.

Limited to U.S. markets; no direct global macro link.

Counterpoint

Despite broad sector weakness, DGX's strong beat could signal a buying opportunity.

Key entities

  • McKesson

    Healthcare distribution giant.

  • AdaptHealth

    Home medical equipment provider.

  • Elevance Health

    Health insurer.

  • Quest Diagnostics

    Diagnostic testing services.

Related articles

$MCKMedAI 8/10

and Getting Worse. Here Are 2 Stocks That Turn Rising Prices Into Rising Profits.

McKesson (MCK) and Cencora (COR) are positioned to benefit from certain drug price inflation due to contractual provisions. McKesson reported $403.4B revenue and $39.11 EPS for fiscal 2026, with Q1 2027 revenue at $105.4B and EPS at $9.93. Cencora generated $321.3B revenue in fiscal 2025, with Q2 revenue at $78.4B and EPS at $4.75. Both companies have raised EPS forecasts.

$DGXHighAI 8/10

Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue?

Quest Diagnostics (DGX) hit a 52-week high, driven by consistent earnings beats. It reported EPS of $3.12 vs. $2.81 estimate, with revenue beating consensus by 2.15%. The company has a Zacks Rank of #2 (Buy) and a VGM Score of B. DGX trades at 21.6X current fiscal year EPS estimates. Option Care Health (OPCH), a peer, also shows strong fundamentals and a Zacks Rank of #2.

$MCKHighAI 9/10

With Price-Increase Clauses, These Two Drug Distributors Can Withstand ‘Trumpflation’

McKesson (MCK) and Cencora (COR) benefit from drug price increases due to inflation-based compensation clauses. McKesson reported $403.4B revenue in 2026, up 12%, and raised EPS guidance. Cencora posted $321.3B revenue in 2025, up 3.8%, and increased EPS guidance. Both companies' contracts allow gains from manufacturer price hikes, but risks include regulation and cost pressures.

$AHCOMedAI 8/10

AdaptHealth Cuts 2026 Outlook as Contract Costs Hit Margins

AdaptHealth Corp. (AHCO) cut its 2026 adjusted EBITDA outlook to $490 million to $520 million from $680 million to $730 million, citing margin pressure from West Coast capitated contract costs and a manufacturer price increase. Revenue guidance is $2.85 billion to $2.89 billion. Q2 organic revenue rose 15.9% to $740.3 million. The company agreed to sell Diabetes Health for $235 million.